Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid for COVID-19 Post-Exposure Prophylaxis
NCT04550338Phase 3Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Tranexamic Acid Treatment with Placebo Treatment (2 arms). Primary endpoint: Conversion from negative to positive COVID-19 test at 7 days. Planned start Aug 2021; status: withdrawn.
02
Drugs
tranexamic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04550338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550338.